JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain
JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain NEWS PROVIDED BY JanOne Inc. 28 Jun, 2023 PR NewsWire https://www.prnewswire.com/news-releases/janone-files-international-patent-application-for-methods-of-using-low-dose-naltrexone-to-treat-chronic-pain-301865422.html Patent filing marks another milestone in becoming a world leader in pain management LAS VEGAS, June 28, 2023 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that […]
How Does Low Dose Naltrexone (LDN) help CRPS?
Are there studies regarding the effectiveness of Low Dose Naltrexone (LDN) for pain relief?
LDN therapy a new hope for people suffering from chronic pain? (in Polish) (News)
LDN therapy a new hope for people suffering from chronic pain? MedExpress Team 17 August 2023 https://www.medexpress.pl/blogosfera/terapia-ldn-nowa-nadzieja-dla-osob-cierpiacych-na-przewlekly-bol/ Chronic pain is one of the most common physical issues impacting up to 25% of the population at various times in their lives. Given that chronic pain can be difficult to treat with conventional methods, doctors and scientists […]
The Utilization of Low Dose Naltrexone for Chronic Pain (Abstract)
The Utilization of Low Dose Naltrexone for Chronic Pain CNS Drugs 28 July 2023 https://pubmed.ncbi.nlm.nih.gov/37505425/ Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that naltrexone […]
JanOnes Innovative Approach to Addressing Chronic Pain Filing International Patent Application for Low Dose Naltrexone (News)
JanOnes Innovative Approach to Addressing Chronic Pain Filing International Patent Application for Low Dose Naltrexone Best Stocks 28 June 2023 https://beststocks.com/janones-innovative-approach-to-addressing-chr/ On June 28, 2023, JanOne made a significant move by filing an international patent application for innovative methods involving the utilization of low dose naltrexone to effectively address chronic pain. This groundbreaking development showcases […]
Low Dose Naltrexone’s Utility for Non-Cancer Centralized Pain Conditions… (Abstract)
Low Dose Naltrexone’s Utility for Non-Cancer Centralized Pain Conditions – A Scoping Review Pain Med 11 June 2023 https://pubmed.ncbi.nlm.nih.gov/37302106/ Background: At low doses, naltrexone (LDN) has been shown to modulate inflammation through the interruption of microglial cell activation within the central nervous system. One of the most likely contributors to centralized pain is changes in […]
Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series (Abstract)
Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series J Pain Res 14 June 2023 https://pubmed.ncbi.nlm.nih.gov/37337611/ Purpose: Low-dose naltrexone (LDN) has increased in popularity as a non-opioid medication that may decrease chronic pain symptoms. LDN is most commonly used to treat fibromyalgia, complex regional pain syndrome (CRPS), and painful diabetic neuropathy. […]
Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia… (Abstract)
Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis Biomedicines As revised 23 March 2023 https://www.mdpi.com/2227-9059/11/4/1087 Current pharmacologic treatments may provide limited analgesia in fibromyalgia and other chronic pain disorders. Low-dose naltrexone (LDN) has emerged as a potential analgesic option that […]
JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians (news)
JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians 22 February 2023 https://www.biospace.com/article/releases/janone-to-present-important-trial-results-at-annual-meeting-of-american-society-of-interventional-pain-physicians/ JAN 123’s in vitro study on low dose naltrexone vies for the Society’s “Best Research Abstract of the Year”. JanOne, a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of […]